PSMA-RLT in Biochemically Recurrent PCa
Conditions: Prostate Cancer Recurrent Interventions: Drug: [177Lu]Lu-PSMA I&T Sponsors: Medical University of Vienna Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 23, 2024 Category: Research Source Type: clinical trials
99mTc-MIP-1404 SPECT/CT in Primary Staging of Prostate Cancer
Conditions: Prostate Cancer Interventions: Diagnostic Test: PSMA-imaging Sponsors: Turku University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 23, 2024 Category: Research Source Type: clinical trials
Retrospective Study to Assess Real-Life Use of The Long Acting GnRH Agonist as Prostate Cancer Treatment
Conditions: Prostate Cancer Sponsors: Chinese University of Hong Kong; Ipsen Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2024 Category: Research Source Type: clinical trials
Geriatric Assessment and Technology Evaluation in Prostate Cancer
Conditions: Prostate Cancer; Prostate Cancer Metastatic Interventions: Other: Questionnaires Sponsors: University of Chicago Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2024 Category: Research Source Type: clinical trials
Evaluation of a Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Conditions: Prostate Carcinoma; Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8 Interventions: Procedure: Computed Tomography; Other: Gallium Ga 68 Gozetotide; Drug: Lutetium Lu 177 Vipivotide Tetraxetan; Procedure: Positron Emission Tomography; Procedure: PSMA PET Scan; Other: Questionnaire Administration; Procedure: Single Photon Emission Computed Tomography Sponsors: Jonsson Comprehensive Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2024 Category: Research Source Type: clinical trials
Retrospective Study to Assess Real-Life Use of The LA GnRH Agonist as Prostate Cancer Treatment
Conditions: Prostate Cancer Sponsors: Chinese University of Hong Kong; Ipsen Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2024 Category: Research Source Type: clinical trials
Primary Care-Based Follow-up of Cancer Survivors of the Prostate and Kidney
Conditions: Prostate Cancer; Kidney Cancer Sponsors: University Hospital, Strasbourg, France Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 19, 2024 Category: Research Source Type: clinical trials
High-Risk Metachronous Oligometastatic Prostate Cancer Trial
Conditions: Prostate Cancer; Oligometastatic Disease Interventions: Drug: niraparib/abiraterone acetate; Radiation: Stereotactic ablative radiation therapy (SABR); Drug: Androgen deprivation therapy (ADT) Sponsors: University of Maryland, Baltimore; Janssen Scientific Affairs, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 19, 2024 Category: Research Source Type: clinical trials
Role of F-18 PSMA in Prostate Cancer Patient
Conditions: Prostatic Neoplasms Interventions: Device: PSMA PET/CT Sponsors: Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 18, 2024 Category: Research Source Type: clinical trials
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Conditions: Biochemically Recurrent Prostate Carcinoma; Oligometastatic Prostate Carcinoma; Recurrent Prostate Adenocarcinoma; Stage IIB Prostate Cancer AJCC v8; Stage IIC Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8 Interventions: Drug: Antiandrogen Therapy; Procedure: Biospecimen Collection; Procedure: Bone Scan; Radiation: Hypofractionated Radiation Therapy; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Radiation: Stereotactic Body Radiation Therapy; Other: Survey Administration Sponsors: Mayo Clinic Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2024 Category: Research Source Type: clinical trials
Effects of Kieser Resistance Training Plus Kieser Pelvic Floor Training vs. Kieser Resistance Training Plus Traditional Pelvic Floor Exercise on Urinary Incontinence in Prostate Cancer Patients After Radical Prostatectomy
Conditions: Prostate Cancer; Prostate Ectomy; Pelvic Floor Disorders; Incontinence, Urinary Interventions: Behavioral: Resistance training including the Kieser A5 pelvic floor trainer; Behavioral: Resistance training without pelvic floor biofeedback Kieser A5 pelvic floor trainer Sponsors: University Hospital Heidelberg; Kieser Training Offenbach / Marko Babovic; Kieser Training AG Z ürich / Dr. David Aguayo Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2024 Category: Research Source Type: clinical trials
New Prostate Cancer Foundation-Funded Research To Speed Up Prostate Cancer Clinical Trials Worldwide
LOS ANGELES, Jan. 11, 2024. New analysis of data published by Susan Halabi, PhD, of Duke University could facilitate approval of new prostate cancer treatments almost two years earlier than the current standard.
The study published online January... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 14, 2024 Category: Pharmaceuticals Source Type: clinical trials
CV CARE: CardioVascular Care in PC Patients
Conditions: Prostate Cancer; Cardiovascular Diseases Interventions: Behavioral: CV Care Program Sponsors: Dana-Farber Cancer Institute; National Comprehensive Cancer Network Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 12, 2024 Category: Research Source Type: clinical trials
An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States
Conditions: Non-metastatic Prostate Cancer; Non-metastatic Castration-resistant Prostate Cancer Interventions: Drug: Darolutamide (Nubeqa, BAY1841788); Drug: Enzalutamide; Drug: Apalutamide Sponsors: Bayer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 12, 2024 Category: Research Source Type: clinical trials
Towards Optimal Treatment for High Risk Prostate Cancer
Conditions: High Risk Prostate Carcinoma Interventions: Radiation: HYPOPRIME treatment Sponsors: Haaglanden Medical Centre; Tata Memorial Centre Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 12, 2024 Category: Research Source Type: clinical trials
